In 2023, weight loss drugs captured the public's attention like never before, with GLP-1 agonists such as Ozempic, Wegovy, Saxenda and Mounjaro leading the conversation.

Beyond their weight loss benefits, this class of drugs has recently begun to make waves for new cardiac indications, broadening their potential impact on public health and payer budgets.

Our latest guide provides critical clinical updates on:

• New players in the weight loss medication space
• Insights and payer trends: will coverage expand in 2024?
• The long-term impact and costs of GLP-1 weight loss therapies, and more!